Leukoerythroblastosis in Castration-Resistant Prostate Cancer: A Clue to Diffuse Bone Marrow Carcinomatosis
Author(s) -
Frank S. Fan,
Chung-Fan Yang
Publication year - 2019
Publication title -
clinics and practice
Language(s) - English
Resource type - Journals
ISSN - 2039-7283
DOI - 10.4081/cp.2019.1124
Subject(s) - medicine , carcinosis , prostate cancer , bone marrow , disseminated intravascular coagulation , partial thromboplastin time , denosumab , pathology , docetaxel , bone metastasis , cancer , oncology , osteoporosis , platelet , peritoneal carcinomatosis , colorectal cancer
A 66-year-old man with a previous history of advanced prostate cancer failing complete androgen blockade, docetaxel chemotherapy, denosumab, and abiraterone acetate as judged by persistent high serum levels of prostate specific antigen presented with exertional dyspnea, normocytic anemia, and thrombocytopenia. Leukoery - throblastosis was noted in his peripheral blood. Bone marrow examination disclosed diffuse bone marrow carcinomatosis from prostate cancer. Prolonged activated partial thromboplastin time, prothrombin time, and an extremely elevated serum level of Ddimer led to a diagnosis of disseminated intravascular coagulation. Magnetic resonance imaging of spine revealed extensive bone marrow involvement but bone scan showed only scanty bony metastasis. We like to call attention to the importance of prompt bone marrow examination once recognizing leukoerythroblastosis in patients with advanced prostate cancer. Survey of a possible coexistent disseminated intravascular coagulation is as well strongly recommended in this condition.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom